Opinion|Videos|March 28, 2025
Tailoring Immunotherapy Strategies for Advanced NSCLC
Panelists discuss how treatment decisions for advanced non–small cell lung cancer (NSCLC) without actionable mutations depend on factors like PD-L1 status, histology (eg, squamous [SQ]), and biomarkers like STK11/KEAP1. Chemotherapy may be added based on individual patient factors, with promising advancements expected in 2025.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you select between mono immunotherapy (IO) and dual IO therapy in patients with advanced NSCLC and no actionable mutations?
- In which patients do you consider the addition of chemotherapy?
- How does PD-L1 status influence your decision?
- What is your preferred management strategy for patients with SQ histology? STK11 or KEAP1? What data influence your treatment approach?
- What advancements in lung cancer from 2024 will have the most significant impact on your clinical practice in 2025?
- What do you see as the greatest treatment gaps and unmet needs in the management of advanced NSCLC, and what are the most promising opportunities for future advancements?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
5